Liver cancer: An evolving challenge reaching research maturity
Jordi Bruix – 25 March 2008
Eltrombopag: Is this “24 karat gold platelet” treatment for thrombocytopenia in cirrhosis associated with hepatitis C?
Amany Zekry, John Freiman – 25 March 2008
Peroxisome proliferator‐activated receptor‐δ induces insulin‐induced gene‐1 and suppresses hepatic lipogenesis in obese diabetic mice
Xiaomei Qin, Xuefen Xie, Yanbo Fan, Jianwei Tian, Youfei Guan, Xian Wang, Yi Zhu, Nanping Wang – 24 March 2008 – Primary nonalcoholic fatty liver disease is one of the most common forms of chronic liver diseases and is associated with insulin‐resistant states such as diabetes and obesity. Recent work has revealed potential implications of peroxisome proliferator‐activated receptor‐δ (PPARδ) in lipid homeostasis and insulin resistance.
Location is everything: The liver stem cell niche
Bryon Petersen, Thomas Shupe – 24 March 2008
Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo‐controlled study in patients with chronic hepatitis C
Stuart K. Roberts, Graham Cooksley, Gregory J. Dore, Richard Robson, David Shaw, Heather Berns, George Hill, Klaus Klumpp, Isabel Najera, Carla Washington – 18 March 2008 – The nucleoside analog R1479 is a potent and highly selective inhibitor of nonstructural protein 5B–directed hepatitis C virus (HCV) replication in vitro. R1626, a tri‐isobutyl ester prodrug of R1479, was developed to increase bioavailability and improve antiviral activity.
Screening for esophageal varices: Endoscopy, other tools, or endoscopy and other tools?
Dominique Thabut, Richard Moreau, Didier Lebrec – 10 March 2008
The optimal interval of endoscopic variceal ligation
Gin‐Ho Lo, Kwok‐Hung Lai – 6 March 2008
Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C
Kirti Shetty, Munira Hussain, Lei Nei, K. Rajender Reddy, Anna S.F. Lok – 6 March 2008 – Occult hepatitis B virus (HBV) infection is defined as the detection of HBV deoxyribonucleic acid (DNA) in the serum or liver tissue of individuals who test negative for hepatitis B surface antigen (HBsAg). We undertook a prospective study to evaluate the significance and course of occult HBV in patients with hepatitis C virus (HCV) cirrhosis undergoing orthotopic liver transplantation (OLT).
Hepatitis C virus reinfection in liver transplant patients: Evaluation of liver damage progression with echo‐color doppler
Massimo Bolognesi, Cristina Quaglio, Giancarlo Bombonato, Maria Guido, Luisa Cavalletto, Liliana Chemello, Carlo Merkel, Massimo Rugge, Angelo Gatta, David Sacerdoti – 6 March 2008 – Liver transplant recipients are a model of rapid progression of hepatitis C virus (HCV)–related liver disease, from normal to cirrhosis. The aim of the study was the analysis of the relationship between portohepatic hemodynamics and modification in liver histology during the progression of HCV liver disease after transplant. Patients transplanted for HCV cirrhosis were considered for the study.
Should trichrome stain be used on all post–liver transplant biopsies with hepatitis c virus infection to estimate the fibrosis score?
David Tretheway, Ashok Jain, Randi LaPoint, Rajeev Sharma, Mark Orloff, Patricia Milot, Adel Bozorgzadeh, Charlotte Ryan – 6 March 2008 – Recurrent hepatitis C is virtually universal after liver transplantation; however, an individual patient's clinical course and disease burden are highly variable and difficult to predict. The fibrosis score determined on posttransplant biopsies appears to be a sensitive and specific marker of disease progression and severity.